• 11/19/2024 - 08:00

  Ikonisys completed a capital increase through a private placement

• 11/18/2024 - 07:30

  Ikonisys Group enters Central America Market through a Partnership and Distribution Agreement with Green Med Panama

• 11/12/2024 - 18:00

  Renewal of the Agreement as European Authorized Representative and Importer for Novodiax’s CE IVD-Certified Real-Time Immunohistochemistry Technology

• 11/04/2024 - 18:00

  Ikonisys to Start Collaboration with SYNLAB Italy to Introduce Ikoniscope in Pathology Laboratories

• 10/31/2024 - 23:00

  Ikonisys publishes its 2024 half-year financial results

• 10/14/2024 - 18:30

  Ikonisys completed a capital increase through a private placement

• 10/10/2024 - 07:30

  Ikonisys announces that Hospitex International won the public tender of the prestigious U.O.C. Pathological Anatomy of Enna in Italy

• 10/03/2024 - 18:00

  Successful 2024 ISO 13485 Certification Maintenance Strengthening Ikonisys’ Strong Market Position and Growth Potential

• 10/01/2024 - 17:45

  Results of the Ordinary Annual and Extraordinary General Meeting of September 30, 2024

• 09/12/2024 - 17:45

  Postponement of the Shareholders’ Meeting to September 30, 2024 and Amendment of the Agenda

• 09/11/2024 - 18:00

  Ikonisys and BIO BRASIL BIOTECNOLOGIA to Strengthen Partnership to Expand Cytology Services in Brazil

• 09/09/2024 - 08:00

  Ikonisys Announces the Launch of Ikoniscope Max in Europe at the 36th European Congress of Pathology in Florence

• 09/04/2024 - 18:00

  Terms and conditions of availability of preparatory documents for the General Meeting of September 25, 2024

• 08/16/2024 - 11:30

  Ikonisys completed a capital increase through a private placement

• 07/18/2024 - 18:30

  Ikonisys completed a capital increase through a private placement

• 07/09/2024 - 17:45

  Ikonisys Announces that Hospitex International Signed Supply Contracts in Italy Marking Growth Potential for the Group

• 07/08/2024 - 17:45

  Availability of the 2023 Annual Report

• 07/02/2024 - 08:30

  Ikonisys reports its Full-Year Financial Results for 2023 and provides an update on its latest developments

• 06/11/2024 - 18:30

  Ikonisys and Ulisse Biomed Announce Strategic Partnership to Support Innovation in Cancer Diagnostics

• 06/03/2024 - 20:45

  Ikonisys closes capital increase through a private placement to further accelerate its commercial development

• 05/30/2024 - 07:30

  Ikonisys Introduces New Website to Highlight Advantages of FISH Technology and Total Automation in Healthcare

• 05/24/2024 - 17:45

  Ikonisys announces postponement of the publication of its 2023 annual financial report

• 05/21/2024 - 18:00

  Ikonisys: Hospitex Expands in Ukraine through a Partnership with Diagen LLC to Fight Cancer

• 05/15/2024 - 07:30

  Ikonisys: Hospitex to obtain international patent for the BLOCKfast cyto-inclusion kit

• 05/03/2024 - 07:45

  Ikonisys announces the postponement of the publication of its annual financial report

• 02/29/2024 - 07:30

  Ikonisys: Hospitex International to partner with Allianz Value for first large-scale screening program dedicated to urinary tract oncology diagnostics in Italy

• 02/19/2024 - 07:30

  Ikonisys announces that Hospitex International won the public tender of the prestigious U.O.C. Pathological Anatomy of Ragusa

• 01/02/2024 - 07:30

  Ikonisys: new production record for Hospitex International

• 12/28/2023 - 18:00

  Ikonisys announces the completion of a private placement to speed up growth following recent pivotal deals

• 12/15/2023 - 07:30

  Ikonisys announces a partnership between Hospitex International and the Pathologists Beyond Borders Association

• 11/30/2023 - 07:30

  Ikonisys to Acquire Hospitex International and Become an Integrated Cancer Diagnostic Leader

• 10/31/2023 - 07:30

  Ikonisys and Biocare Medical Forge Alliance: Amplifying Global FISH Diagnostics with Advanced Fluorescent Scopes

• 10/30/2023 - 07:30

  Ikonisys publishes its 2023 half-year financial results and reviews its operational and strategic deployments

• 10/16/2023 - 18:05

  Ikonisys successfully completed its ISO certification reaffirming its ability to continuously meet quality international standard requirements

• 10/10/2023 - 07:30

  Successful study in collaboration with the Neag Cancer Center of UConn School of Medicine demonstrates the power of the Ikoniscope platform for detection of extremely rare cells in the field of immuno-oncology

• 08/03/2023 - 18:26

  Ikonisys announces the completion of new financing via the issuance of a €0.5m private Note

• 07/31/2023 - 07:30

  Ikonisys presents an update of its global activity in the context of its recent technological and commercial milestones

• 07/31/2023 - 07:00

  Increase in the resources allocated to the liquidity contract entrusted to Invest Securities

• 07/26/2023 - 18:02

  Half-yearly report on the Ikonisys liquidity contract at 30/06/2023

• 06/30/2023 - 17:47

  Ikonisys announces the results of its Ordinary Annual and Extraordinary General Meeting of June 28, 2023

• 06/21/2023 - 18:50

  Ikonisys announces the first sale of the Ikoniscope20max solution

• 06/15/2023 - 08:00

  Ikonisys announces the completion of a private placement to accelerate its commercial development

• 04/29/2023 - 22:06

  Ikonisys publishes its Full-Year Financial Results for 2022 and provides an update on its latest developments

• 02/01/2023 - 11:15

  Ikonisys and Integrated Gulf Biosystems Group enter into Distribution Collaboration for Distribution of the Ikoniscope20 System in the Middle East Market

• 11/14/2022 - 18:28

  Ikonisys announces the launch of its instrument for high-volume customers, the Ikoniscope20max

• 10/27/2022 - 17:45

  Ikonisys publishes its 2022 half-year financial results and reviews its operational deployments

• 10/05/2022 - 23:19

  Ikonisys has signed a financing agreement of up to €5.1m of aggregate principal amount to continue its commercial and development strategy and has drawn down a first tranche

• 09/26/2022 - 18:00

  Ikonisys announces the installation of the Ikoniscope20 solution at a US leading urology laboratory

• 09/21/2022 - 14:19

  Ikonisys and Negma Group announce the end of their financing agreement

• 09/13/2022 - 18:47

  Ikonisys announces the start of a Distribution Collaboration with BioVendor Laboratory Medicine for Distribution of the Ikoniscope20 System in the Eastern European Market

• 07/26/2022 - 18:00

  Ikonisys reinforces its strategic collaboration with Empire Genomics following excellent results of optimized reagents in detection of bladder cancer cells

• 06/22/2022 - 18:00

  Ikonisys announces the first sale of the Ikoniscope20 solution including the newly added reagents to Comprehensive Urology

• 05/24/2022 - 18:00

  Ikonisys signs contract and initiates research activities with Politecnico di Milano, a world leading public scientific-technological university in the field of computer science and bioengineering

• 05/12/2022 - 18:30

  Ikonisys Partners With Evosciences Leasing To Support The Commercial Expansion In Europe And The Usa Of The Ikoniscope20

• 05/04/2022 - 23:00

  Ikonisys has signed a financing agreement of up to €6m of aggregate nominal amount to continue the commercial roll-out map

• 04/29/2022 - 20:00

  Ikonisys publishes its Full-Year Financial Results for 2021 and provides an update on its latest developments

• 03/29/2022 - 17:45

  Ikonisys announces its participation in the Investor Access forum

• 02/16/2022 - 18:30

  The Ikoniscope20 preliminary results obtained with University of Connecticut School of Medicine (Neag Cancer Center of UConn) in detecting rare cells surpass the standards of test in immuno-oncology

• 02/07/2022 - 18:45

  Ikonisys announces the successfull installation of the Ikoniscope20 at Tomalab, one of the largest genetic laboratories in Italy

• 02/01/2022 - 18:00

  Ikonisys SA announces the appointment of Gabriel Plan as France sales Director

• 01/26/2022 - 18:30

  Ikonisys announces the initation of coverage of its stock by Sphene Capital

• 10/29/2021 - 18:00

  Ikonisys publishes its half-year financial results for 2021 and provides an update on its developments since its IPO

• 09/30/2021 - 17:45

  Ikonisys sa welcomes us sales director, accelerating its growth and expansion plans in the usa

• 09/06/2021 - 17:45

  Initial results of a study, in collaboration with the uconn school of medicine, highlight the potential of ikonisys’ cell-based diagnostic platform in immuno-oncology

• 09/06/2021 - 17:45

  Initial results of a study, in collaboration with the uconn school of medicine, highlight the potential of ikonisys’ cell-based diagnostic platform in immuno-oncology

• 07/13/2021 - 19:30

  Succes of Ikonisys' initial public offering on Euronext Growth® Paris